Sucampo Pharmaceuticals (NASDAQ:SCMP) had its target price raised by investment analysts at B. Riley from $14.00 to $18.00 in a research report issued on Wednesday, MarketBeat reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price objective indicates a potential upside of 20.40% from the stock’s previous close.

A number of other research analysts also recently commented on SCMP. BidaskClub raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday. ValuEngine raised Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, December 1st. Maxim Group reaffirmed a “buy” rating and issued a $23.00 price target (up previously from $21.00) on shares of Sucampo Pharmaceuticals in a research note on Tuesday, August 8th. Leerink Swann assumed coverage on Sucampo Pharmaceuticals in a research note on Monday, August 21st. They issued an “outperform” rating and a $15.00 price target for the company. Finally, Mizuho downgraded Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $16.40.

Sucampo Pharmaceuticals (NASDAQ SCMP) traded up $0.75 on Wednesday, hitting $14.95. The stock had a trading volume of 5,461,147 shares, compared to its average volume of 725,432. Sucampo Pharmaceuticals has a 12 month low of $9.30 and a 12 month high of $17.24. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The firm has a market capitalization of $627.25, a P/E ratio of 9.21, a P/E/G ratio of 4.00 and a beta of 1.47.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, beating the Zacks’ consensus estimate of $0.25 by $0.02. The business had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. Sucampo Pharmaceuticals’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 earnings per share. sell-side analysts expect that Sucampo Pharmaceuticals will post 1.12 EPS for the current year.

In other Sucampo Pharmaceuticals news, major shareholder Sachiko Kuno sold 1,000,000 shares of Sucampo Pharmaceuticals stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $12.00, for a total value of $12,000,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 4.13% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in SCMP. Vanguard Group Inc. grew its position in Sucampo Pharmaceuticals by 48.9% in the first quarter. Vanguard Group Inc. now owns 1,456,787 shares of the biopharmaceutical company’s stock valued at $16,024,000 after acquiring an additional 478,226 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in Sucampo Pharmaceuticals by 2.3% in the first quarter. Schwab Charles Investment Management Inc. now owns 180,303 shares of the biopharmaceutical company’s stock valued at $1,984,000 after acquiring an additional 4,104 shares during the last quarter. Capstone Asset Management Co. grew its position in Sucampo Pharmaceuticals by 2.1% in the second quarter. Capstone Asset Management Co. now owns 12,360 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 260 shares during the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of Sucampo Pharmaceuticals by 1.0% during the second quarter. Louisiana State Employees Retirement System now owns 10,200 shares of the biopharmaceutical company’s stock worth $107,000 after purchasing an additional 100 shares during the last quarter. Finally, Strs Ohio grew its holdings in shares of Sucampo Pharmaceuticals by 34.4% during the second quarter. Strs Ohio now owns 60,900 shares of the biopharmaceutical company’s stock worth $639,000 after purchasing an additional 15,600 shares during the last quarter. Hedge funds and other institutional investors own 65.31% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/06/sucampo-pharmaceuticals-scmp-pt-raised-to-18-00-at-b-riley.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.